Coronavirus Watch: FDA panel recommends fourth COVID vaccine option
An FDA advisory committee recommended Tuesday that a fourth COVID-19 vaccine be authorized for use in the U.S., this one from the company Novavax.
The vaccine, which was supported by $1.8 billion in taxpayer funding, relies on a more traditional approach than the vaccines from Moderna and Pfizer-BioNTech, which have been used by more than three-quarters of Americans.
According to polling data, 73% of Americans want more vaccine choices.
Read the full story from reporter Karen Weintraub here.
It's Thursday, and this is Coronavirus Watch from the Paste BN Network. Here's more news to know:
- The White House on Thursday laid out plans to distribute low-dose vaccines for children ages 6 months to under 5, the last major group of Americans to receive access to the shots.
- Moderna released data Wednesday showing its newest combination COVID-19 vaccine protects against the highly transmissible omicron variant and called the vaccine its “lead candidate” for a booster this fall.
- Britain's Prime Minister Boris Johnson survived a no-confidence vote called by opposition party leaders in part over allegations of drunken government parties held during COVID-19 lockdowns.
See our COVID-19 resource guide here. See total reported cases and deaths here. On vaccinations: About 78% of people in the U.S. have received at least one vaccine shot, and about 67% are fully vaccinated, according to the CDC.
– Cady Stanton, Paste BN Nation NOW reporter, @cady_stanton